GlassScriptPhysician profile
Michael A Wilson
NPI 1518578202
$1,184.98
in general payments reported to CMS, 2019-2025
21 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.27 · 2023: $20.00 · 2024: $308 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.99 | 2024-2025 | |
| Eisai INC. | $103.79 | 2025 | |
| Mallinckrodt Hospital Products INC. | $66.68 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $57.34 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $53.46 | 2025 | Wainua |
| Emd Serono, INC. | $53.27 | 2024 | |
| Neurocrine Biosciences, INC. | $40.60 | 2024-2025 | Ingrezza |
| Genentech USA, INC. | $38.63 | 2025 | Ocrevus Zunovo |
| Ani Pharmaceuticals, INC. | $34.88 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $33.89 | 2025 | |
| Merz Pharmaceuticals, LLC | $31.40 | 2025 | Xeomin, Inbrija, Ampyra |
| Ge Healthcare | $31.17 | 2025 | |
| Tanabe Pharma America, INC. | $30.00 | 2025 | Radicava |
| Janssen Biotech, INC. | $25.73 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $25.45 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $23.70 | 2025 | Symbravo |
| Tg Therapeutics, INC. | $22.99 | 2025 | |
| Amgen INC. | $22.25 | 2025 | Uplizna |
| Tris Pharma INC | $18.06 | 2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $15.78 | 2025 | Austedo Xr |
| Alexion Pharmaceuticals, INC. | $13.65 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.